Alpa Laboratories Ltd

Alpa Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 September 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Alpa Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Alpa Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters deteriorate significantly, prompting a downgrade to a Strong Sell rating. With its price-to-earnings (P/E) ratio rising to 32.77 and price-to-book value (P/BV) at 0.71, the stock now appears riskier compared to its historical averages and peer group, reflecting growing investor caution amid underwhelming returns and sector headwinds.

Alpa Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a significant deterioration in its recent quarterly financial performance. The company’s latest results for June 2026 reveal a marked decline in revenue, profitability, and key return metrics, signalling a shift from a previously flat to a negative financial trend. This downturn comes amid broader sector pressures and contrasts sharply with benchmark indices such as the Sensex.

Alpa Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 August 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Alpa Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 30 July 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Alpa Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 July 2026, providing investors with an up-to-date perspective on its performance and outlook.

Alpa Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 07 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Alpa Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Alpa Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Alpa Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from a risky to an attractive valuation grade. This change, coupled with its current price-to-earnings (P/E) ratio of 9.85 and price-to-book value (P/BV) of 0.79, positions the stock as a potentially undervalued opportunity relative to its historical averages and peer group.

Alpa Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 June 2026, providing investors with the latest insights into the company’s performance and outlook.

Alpa Laboratories Ltd., a micro-cap pharmaceutical manufacturer with a market capitalisation of ₹148.00 crores, reported a net profit of ₹1.38 crores for Q4 FY26, marking a sharp recovery from the previous year's loss of ₹2.12 crores. However, the positive earnings reversal conceals troubling revenue trends, as net sales declined 21.34% year-on-year to ₹31.40 crores, raising questions about the sustainability of the company's business momentum in an otherwise buoyant pharmaceutical sector.

Alpa Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 17 Nov 2025, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 20 May 2026, providing investors with the latest perspective on the company’s position.

Alpa Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 09 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Alpa Laboratories Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 17 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 April 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Alpa Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 17 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 17 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.